Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that depletion of eIF5B sensitizes glioblastoma multiforme cells to TRAIL-induced apoptosis by a pathway involving caspases-8, -9, and -7, with no significant effect on cell cycle progression. eIF5B promotes evasion of apoptosis by promoting the translation of several IRES-containing mRNAs, encoding the antiapoptotic proteins XIAP, Bcl-xL, cIAP1, and c-FLIP<sub>S</sub>.
|
30670698 |
2019 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our current findings show that these biologic delivery vehicles have high tumor tropism efficacy and expression TRAIL gene under the trigger of TGF-β-secreting GBMs, as well as avoid unspecific TRAIL secretion into normal brain tissue. hAMSC-SBE4-TRAIL inhibited the proliferation and induced apoptosis in experimental GBMs both in vitro and in vivo.
|
30867058 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analyses of apoptotic signaling events revealed that pinoresinol enhanced the formation of TRAIL-mediated death-inducing signaling complex (DISC) and complete processing of procaspase-8 within the DISC in glioblastoma cells, in which caspase-8 was inactivated.
|
31534206 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apart from genetic changes in DR4-Ser424, we further classified various cancer cell lines originated from stomach, colon, lung, and glioblastoma according to their sensitivity to and receptor preference upon TRAIL death signaling and generated TRAIL-tolerant persister-derived DLD-1<sup>PER</sup> cells.
|
30987996 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
|
31319548 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, this study provides evidence for the further development of metal-based anticancer agents and chemosensitizers of TRAIL for the treatment of human glioblastoma cancer cells.
|
29963768 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
This combinational therapy through PEI-PLL-transfected mesenchymal stem cells can provide cost-effective, low immunogenic, and tumor-targeted delivery of suicideal genes (HSV-TK and TRAIL) for promising glioblastoma treatment.
|
30223091 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results identify the novel C27OAs as TRAIL sensitizers targeting the upstream DISC assembly of DR5, and provide a rationale for further development of C27OAs for facilitating TRAIL-based chemotherapy in glioblastoma patients.
|
30359578 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, our findings show that H5CmTERT-Ad/TRAIL can promote dispersion of an oncolytic adenovirus through robust induction of apoptosis in a highly TRAIL-resistant glioblastoma.
|
29362367 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells.
|
29777390 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism.
|
30385739 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
To define the novel pathways that regulate susceptibility to TRAIL in GBM cells, we performed a genome-wide expression profiling of microRNAs in GBM cell lines with the distinct sensitivity to TRAIL-induced apoptosis.
|
28459998 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data demonstrate that miR-133a promotes TRAIL resistance in glioblastoma by suppressing DR5 expression and activating NF-κB signaling.
|
28918048 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
This work thus demonstrates the ability of oHSV-TRAIL to overcome the therapeutic resistance and recurrence of GBM, and provides a basis for its testing in a GBM clinical trial.
|
28567859 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We designed an adeno-associated virus (AAV) vector for intracranial delivery of secreted, soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) to GBM tumors in mice and combined it with the TRAIL-sensitizing cardiac glycoside, lanatoside C (lan C).
|
26708508 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sensitizing effects of PARP inhibition on TRAIL-mediated apoptosis and potential toxicity were analyzed using viability assays and flow cytometry in established GBM cell lines, low-passage neurospheres and astrocytes in vitro.
|
25531448 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant decrease in tumor growth and a subsequent increase in survival were observed when mice bearing highly aggressive GBM were treated with MSC coexpressing S-TRAIL and HSV-TK.
|
23389839 |
2013 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, SC-delivered immunoconjugates of ENb and TRAIL target a wide spectrum of GBM cell types with varying degrees of TRAIL resistance and significantly reduce GBM growth and invasion in both established and primary invasive GBM in mice.
|
23012408 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we developed for the first time a novel vector CRAd5/11-D24.TRAIL/arresten by the following strategies: (1) modify CRAd5-D24 with Ad5/11 chimeric fiber to improve its infection efficiency for glioblastoma; and (2) insert two transgene expression cassettes into the E3 region and the region between the fiber and E4, respectively, for an enhanced therapeutic effect.
|
22136065 |
2012 |
Glioblastoma Multiforme
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP.
|
21877938 |
2011 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro.
|
20623264 |
2010 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we will, after briefly detailing the biology of TRAIL/TRAIL receptor signalling, focus on the promises and pitfalls of recombinant TRAIL as a therapeutic agent alone and in combinatorial therapeutic approaches for GBM.
|
20102513 |
2010 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data provide a mechanism-based rationale for combining targeted toxins and TRAIL receptor agonists to treat GBM.
|
19449148 |
2009 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that therapy with TRAIL, either as monotherapy or in combination with demethylating agents, is not effective in treating glioblastoma because SCGs are not targeted by such treatment.
|
19214542 |
2009 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, shWTE5 significantly enhanced apoptosis induced by chemotherapeutic agents, doxorubicin (DOX) and etoposide (ETP), or by death ligand TRAIL in all of the four solid tumor cells examined (HT-1080, LU99B, TYK and A172).
|
18292948 |
2008 |